培元抗癌汤联合芒硝外敷、腹腔穿刺术治疗恶性腹腔积液疗效观察
DOI:
CSTR:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R730.6

基金项目:

浙江省中医药科技计划项目(2023ZL678)


Observation on Curative Effect of Peiyuan Kangai Decoction Combined with External Application of Natrii Sulfas and Abdominocentesis on Malignant Peritoneal Effusion
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察培元抗癌汤联合芒硝外敷、腹腔穿刺术治疗恶性腹腔积液的临床疗效及对肿瘤标志物、 免疫T淋巴细胞水平的影响。方法:选取2020年6月—2023年12月瑞安市中医院收治的106例恶性腹腔积液患 者,按照随机数字表法分为对照组50例与治疗组56例。所有患者均行胸腔穿刺术,对照组行术后西医化疗+芒 硝外敷治疗,治疗组在对照组基础上联合培元抗癌汤内服。治疗4周后,比较2组临床疗效、中医证候评分、 肿瘤标志物[人鳞状细胞癌相关抗原(SCC)、癌抗原125(CA125)、细胞角蛋白19片段(CYFRA21-1)]水平、 免疫T淋巴细胞 (CD4 + 、CD8 + 、CD4 + /CD8 + ) 水平及不良反应发生情况。结果:治疗组疾病控制率为91.07% (51/56),对照组为74.00%(37/50),2组比较,差异有统计学意义(P<0.05)。治疗后,2组腹部胀满、腰膝 酸软、畏寒肢冷等中医证候评分均较治疗前降低(P<0.05),且治疗组各项评分均低于对照组(P<0.05)。治 疗后,2组SCC、CA125、CYFRA21-1水平均较治疗前降低 (P<0.05),且治疗组SCC、CA125、CYFRA21-1 水平均低于对照组(P<0.05)。治疗后,2组CD4 + 、CD4 + /CD8 + 水平均较治疗前升高(P<0.05),CD8 + 水平较治 疗前下降 (P<0.05);且治疗组 CD4 + 、CD4 + /CD8 + 水平高于对照组 (P<0.05),CD8 + 水平低于对照组 (P< 0.05)。治疗组总不良反应发生率为7.14% (4/56),对照组为22.00% (11/50),2组比较,差异有统计学意义 (P<0.05)。结论:培元抗癌汤联合芒硝外敷、腹腔穿刺术治疗恶性腹腔积液疗效显著,可有效改善患者中医 证候及免疫功能,降低肿瘤标志物水平,且不良反应相对较少。

    Abstract:

    Abstract: Objective: To observe the clinical effect of Peiyuan Kangai Decoction combined with external application of Natrii Sulfas and abdominocentesis on malignant peritoneal effusion,and its effects on the levels of tumor markers and immune T lymphocytes. Methods: A total of 106 cases of patients with malignant peritoneal effusion treated at Ruian Hospital of Traditional Chinese Medicine from June 2020 to December 2023 were selected and divided into the control group(50 cases)and the treatment group(56 cases)using the random number table method. The control group received conventional abdominocentesis and standard western medical treatment,and the treatment group was additionally given the oral administration of Peiyuan Kangai Decoction and external application of Natrii Sulfas based on the control group's treatment. After four weeks of treatment, clinical effects, traditional Chinese medicine(TCM) syndrome scores,tumor markers [squamous cell carcinoma antigen(SCC),cancer antigen 125(CA125),cytokeratin 19 fragment(CYFRA21-1)],immune T lymphocytes(CD4 + ,CD8 + ,CD4 + /CD8 + )levels,and adverse reactions were compared between the two groups. Results:The disease control rate was 91.07%(51/56)in the treatment group and 74.00%(37/50)in the control group,with a significant difference between the two groups(P<0.05). After treatment, the TCM syndrome scores for abdominal distension,soreness and weakness of waist and knees,and fear of cold and cold limbs in the two groups were decreased when compared with those before treatment(P<0.05),with the treatment group showing lower scores than the control group(P<0.05). After treatment, the levels of SCC, CA125, and CYFRA21-1 in the two groups reduced when compared with those before treatment(P<0.05),with the treatment group showing lower levels than the control group(P<0.05). After treatment,the levels of CD4 + and CD4 + /CD8 + in the two groups were increased when compared with those before treatment,and CD8 + levels were decreased when compared with those before treatment(P<0.05),with the treatment group showing higher levels of CD4 + and CD4 + /CD8 + and lower CD8 + level than the control group(P<0.05). The total incidence of adverse reactions was 7.14%(4/56)in the treatment group and 22.00%(11/50)in the control group,with a significant difference between the two groups(P< 0.05). Conclusion:Peiyuan Kangai Decoction combined with external application of Natrii Sulfas and abdominocentesis has a significant curative effect in treating malignant peritoneal effusion. It can significantly improve TCM syndromes and immune function and reduce tumor marker levels,with fewer adverse reactions.

    参考文献
    相似文献
    引证文献
引用本文

姚舒婷,陈国忠,蔡晓鹤.培元抗癌汤联合芒硝外敷、腹腔穿刺术治疗恶性腹腔积液疗效观察[J].新中医,2025,57(16):131-135

复制
相关视频

分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2025-08-26
  • 出版日期:
文章二维码